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Background: The prevalence of AIDS-related lymphoma (ARL) is increasing in South Korea.
The aim of this study is to identify the clinical features of ARL in South Korea.
Methods: From 1998 through 2006, we retrospectively analysed a total of 23 cases of ARL
from seven institutions.
Results: The patients consisted of 20 males and 3 females at a median age of 40 (range,
20–72) on diagnosis of AIDS. ARL developed at their median age of 41 (range, 24–72). The
histological diagnosis was aggressive B cell lymphoma in the majority, but rare T cell and NK/
T cell lymphoma were also included. Ten of 23 (43.5%) was receiving highly active anti-retro-
viral therapy (HAART) before the diagnosis of ARL. Fifteen of twenty-three patients were
given combination chemotherapy with/without radiation, four were given radiation alone, and
four did not receive any treatment against medical advice. Of 20 patients followed-up, nine
were alive in remission, two alive in disease, one died of treatment related complication, four
died of progressive lymphoma, four died of AIDS related causes. The response to treatment
included CR in eight (44.4%), PR in four (22.2%) and PD in three (16.7%). The response to
HARRT was evaluable in 13 patients based on CD4þ cell count and HIV viral load, among
which nine (69.2%) responded. Estimated median survival time was 43.9 months.
Conclusions: Although the population of patients is small, this is the first clinical data ana-
lyses of Korean ARL patients. As a substantial portion of the patients remains alive disease
free, the impact of HAART on the clinical course of ARL needs further follow-up and
evaluation.
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INTRODUCTION
Since 1985 when non-Hodgkin lymphoma (NHL) was
included in the list of an acquired immunodeﬁciency syn-
drome (AIDS)-deﬁning illness, the human immunodeﬁciency
virus (HIV) epidemic has changed much. With the
remarkable decrease in the incidence of opportunistic infec-
tions owing to the advent of highly active anti-retroviral
therapy (HAART), AIDS-related lymphoma (ARL) has
emerged as the second most common cancer associated with
HIV after Kaposi sarcoma (1). Recent large cohort studies
showed that standardized incidence ratios for ARL were
between 20 and 25 (2,3), ﬁndings indicative of a consistent
increase in HAART era. Although HAART has resulted in a
decline in the incidence of HIV-associated cancers as well,
systemic NHL has remained a more common initial manifes-
tation of the AIDS than ever (4). The World Health
Organization has classiﬁed these AIDS-deﬁning lymphomas
into three categories: lymphomas also occurring in
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immunocompetent people, lymphomas more speciﬁcally
related to HIV and lymphomas also occurring in other forms
of immunodeﬁciency (5). Before the introduction of
HAART, the prognosis of ARL was very poor, because the
course of disease was more inﬂuenced by compromised
immune status rather than by lymphoma per se. HAART has
now proven as important component of therapy for ARL (6).
The beneﬁcial impact of HAART resides not only on the
incidence of ARL but also on the therapeutic outcomes in
ARL. This is partly due to the decrease in the incidence of
opportunistic infections and also overall HIV-related mor-
tality (7). The therapeutic strategy continues to improve in
parallel with advance in insights into the pathophysiology as
well as treatment modality.
As of December 2006, a total of 4580 cumulative AIDS
patients were reported in South Korea to the Korean Center
for Disease Control with continuous increase in annual inci-
dence (8). The prevalence of ARL in South Korea must have
increased as well in parallel with AIDS. We attempted to
perform a retrospective analysis for an overview of ARL in
South Korea on the behalf of Korean Society of Hematology
Lymphoma Working Party (KSHLWP).
PATIENTS AND METHODS
PATIENTS
From August 1998 through July 2006, a total of 23 cases of
ARL were treated at eight institutions participating in
KSHLWP. A retrospective review of medical record of these
patients using standardized case report form (CRF) was per-
formed. CRF required all patients to be HIV-seropositive by
enzyme-linked immunosorbent assay as well as conﬁrmed
by Western blot, and their lymphoma histologically or cyto-
logically proven. Clinical data were analysed based on the
clinical records and CRF including age, gender, Ann Arbor
stage, B symptoms, performance status according to the
Eastern Cooperative Oncology Group (ECOG) scale, serum
lactate dehydrogenase (LDH) level, cerebrospinal ﬂuid
analysis, prior diagnosis of AIDS, prior HAART, regimen of
HAART, response to HAART measured by CD4þ cell
count and HIV viral load, treatment of AIDS and ARL,
response to initial treatment and histopathological subtype.
The assessment of response was based on the International
Workshop Response Criteria (9).
STATISTICAL ANALYSES
Overall survival (OS) was deﬁned as the duration between
the dates of diagnosis and death from any cause.
Progression-free survival (PFS) was deﬁned as the duration
from the date of diagnosis to the date of disease progression,
relapse or death from any cause. All survival curves were
evaluated by the Kaplan–Meier method. A log-rank test was
used in a univariate analysis to identify factors affecting sur-
vival. A P-value of 0.05 or less was considered to be
indicative of a statistical signiﬁcance. All statistical analyses
were performed using SPSS version 12.0.
RESULTS
PATIENT CHARACTERISTICS
The demographic and clinical characteristics of the 23
patients are summarized in Table 1. There were 20 male
patients and three female patients with a median age of 41
years (range: 24–72) at the diagnosis of ARL and a median
age of 40 years (range: 20–72) at the diagnosis of AIDS. A
median interval between the diagnosis of AIDS and that of
ARL was 7.6 months (range: 0–72.0). Eleven patients were
given HAART before the diagnosis of ARL. Another eight
patients were given HAART within 1 month from the diag-
nosis of ARL. And all the patients were eventually given
HAART regardless of the time when the diagnosis of ARL
was made. Eight patients presented with ARL as the primary
AIDS-deﬁning illness. None of the patients had a history of
KS. The median CD4þ cell count was 46  106/l (range,
3–368) and the median HIV viral load was 84 000 copies/
ml (range, 1422–2 800 000). Nine patients (39.1%) had B
symptom, 13 patients (56.5%) showed elevated serum LDH
values. CSF study was done in eight patients, one of whom
revealed evidence of lymphomatous meningitis. Eight
Table 1. Patient demographic and clinical characteristics
Median (range)
Gender M/F 20/3
Age at AIDS diagnosis 40 (20–72)












Serum LDH level. normal 13 (56.5%)
CD4 count at diagnosis (x106/l) 46 (3–368)
HIV viral load at diagnosis (copy/ml) 84 000 (1422–2 800 000)
AIDS: acquired immunodeﬁciency syndrome
ARL: AIDS-related lymphoma
ECOG: Eastern Cooperative Oncology Group
LDH: lactate dehydrogenase
HIV: human immunodeﬁciency virus





















patients presented in stage I disease, four patients in stage II,
three patients in stage III and three patients in stage IV
(Table 1).
HISTOPATHOLOGICAL SUBTYPES
The results of the histopathological diagnoses of all the
patients are summarized in Table 2. DLBCL including
PCNSL was the most common histopathological ARL
subtype (14 of 23 patients; 61%). Lymphomas associated
more speciﬁcally with HIV were diagnosed in two patients
(primary effusion lymphoma and plasmablastic lymphoma).
Our series included diagnosis of uncommon T-cell lympho-
mas or Hodgkin lymphoma. A case of just ‘B-cell lym-
phoma, unclassiﬁed’ diagnosed on the biopsy from perianal
skin lesion showed immunohistochemical staining positive
for kappa light chain and negative for lambda light chain,
CD20, CD45, CD3, CD30 and CD56. In this case, a possi-
bility of plasmacytoma and plasmablastic lymphoma should
be considered.
INITIAL TREATMENT
Among the 23 patients, four patients were not given any
treatment because of poor general condition or patients’
refusal. Standard dose CHOP chemotherapy (cyclophospha-
mide [CPA], doxorubicin [DOX], vincristine [VCR] and pre-
dnisolone [PRED]) was given to ﬁve patients. Chemotherapy
using mBACOD (CPA, VCR, DOX, bleomycin [BLEO] and
methotrexate [MTX]) was given to four patients and
CEOP-B (CPA, epirubicin, VCR, PRED and BLEO) to
4. Two case of Burkitt’s lymphoma were treated with
CODOX-M/IVAC (CPA, VCR, DOX and MTX/ifosphamide,
etoposide [ETO]) and EPOCH (ETO, DOX, VCR, CPA,
PRED). Rituximab was not given to any patients. Seven of
the 19 treated patients received radiotherapy (RT) at a
median dose of 45 Gy (range: 30–60.4). Three patients who
had stage I or II disease received radiation therapy alone.
Treatments for the patients are summarized in Table 3.
RESPONSE TO TREATMENT, SURVIVAL RATES
A total of 18 patients were available for the evaluation of
their response to initial treatment. Five patients were
excluded from the assessment for the reasons as follows:
four patients with no treatment at all, and one patient lost to
follow-up before response evaluation. The median follow-up
duration was 9.2 months (range: 0.5–62.4). The overall
response rate (ORR) for all evaluable patients was 66.7% as
eight patients (44.4%) achieved CR and four patients (22.2%)
achieved PR. Three patients (16.7%) whose diagnoses were
DLBCL and PCNSL showed PD despite treatment.
Ten patients (43.5%) were alive at the time of the last
follow-up. Nine of them showed no progression of disease
including six patients in CR and three in PR after initial
treatment. One patient who developed lymphomatous menin-
gitis despite initial chemotherapy was alive receiving
intrathecal (IT) chemotherapy at the time of last follow-up.
One patient who showed CR after initial chemotherapy died
of AIDS progression. One patient who showed PD on che-
motherapy was lost to follow-up. The estimated OS of all 23
patients from the beginning of treatment was 43.9 months
and estimated 3-year OS rate was 56.1%. (Fig. 1)
Response assessment of HAART by the titration of HIV
viral copy number and/or the CD4þ cell count was available
in 15 patients. Twelve patients (80.0%) showed sustained
response, while three patients (20.0%) did not respond.
Table 2. Pathologic diagnosis
Pathologic diagnosis Number of patients
Diffuse large B cell lymphoma 14 (Primary CNS lymphoma, 4)
Burkitt lymphoma 2
Peripheral T cell lymphoma 2
Primary effusion lymphoma 1
Plasmablastic lymphoma of the oral cavity 1
NK/T cell lymphoma 1
Hodgkin lymphoma 1
B cell lymphoma, unclassiﬁed 1
Total 23
CNS: central nervous system
Table 3. Treatment regimens











CHOP: cyclophosphamide, doxorubicin, vincristine, prednisone
mBACOD: methotrexate, bleomycin, doxorubicin, cyclophosphamide,
vincristine
RT: radiotherapy
CEOP-B: cyclophosphamide, epirubicin, vincristine, prednisolone and
bleomycin
CODOX-M/IVAC: cyclophosphamide, vincristine, doxorubicin and
methotrexate/ifosphamide, etoposide
EPOCH: etoposide, doxorubicin, vincristine, cyclophosphamide,
prednisolone





















There was a difference statistically not meaningful in the
median survival duration (MSD) between two groups (not
reached versus 20.7 months, P ¼ 0.34).
PROPHYLACTIC MEASURES
Trimethoprim–sulfamethoxazole was given to 10 (55.5%) of
18 evaluable patients for Pneumocystis jirovecii prophylaxis.
And IT chemoprophylaxis was given to only 2 (11.8%) out
of 17 evaluable patients.
DISCUSSION
This is the ﬁrst case series of ARL in South Korea. The
incidence of ARL is so rare in AIDS-pauci area like South
Korea that many important issues remain uninvestigated.
There have been few reports on Korean ARL patients. The
ﬁrst report focused on spectrum of opportunistic infections
and malignancies in AIDS patients, and one with Primary
CNS lymphoma (PCNSL) and one with tongue lymphoma
were included (10). And the second one concerned about
neurologic complications of HIV infection and two presump-
tively diagnosed as having PCNSL were included (11). A
retrospective report showed that there were 13 NHL and 3
HD patients out of a total of 850 AIDS patients over 20 year
period (12). But these data were from a single institution and
lack of detailed information, such as histologic subtypes and
treatments. Also we found few anecdotal reports published
on Korean journals, one of them was included in this analy-
sis in part (13), and clinical characteristics of the other
patients are summarized in Table 4 (14–18). The spectrum
of clinical presentation of ARL varies from localized disease
conﬁned in CNS or pleura to disseminated systemic disease.
Our series showed a broad spectrum of clinical manifes-
tations. The major histologic type was diffuse large cell lym-
phoma of B-cell phenotype; low grade histology was rare. It
is of note that our series contain rare T-cell or NK/T cell
lymphomas. Registry data from 11 American regions showed
a rate of T-cell lymphoma of 1.4% from a total of 6788
cases of ARL (19). The majority included Mycosis fun-
goides and peripheral T-cell lymphoma.
Prognostic factors of ARL patients were amended after the
introduction of HAART. Before the HAART era, the most
important predictor of survival was the immune status, rep-
resented by the total number of CD4-positive lymphocytes
(20). The uniformly poor prognosis of the ARL was related
to the limitation in employing standard chemotherapy. The
dose intensity of chemotherapy used in immune competent
patients frequently aggravates existing profound immune
compromise of ARL patients inviting severe infection (1).
That explains why the aim of the chemotherapy in these
patients was often palliative rather than curative. Once
HAART was introduced, the immune function of the patients
dramatically improved so as to alter the prognostic factors.
Analysis of 111 patients treated with HAART indicated on
Table 4. Clinical characteristics of cases with ARL reported in South Korea
Author Age/
sex





Song 33/M Immunoblastic B cell
lymphoma
IVAE Bone Yes Radiation followed by
mBACOD
53 Yes 1998 14
Han 52/M Immunoblastic B cell
lymphoma
N/A Tongue Yes None 30 No 1999 15
Oh 63/F Diffuse large B cell
lymphoma
IAE Stomach Yes Gastrectomy followed
by COPP
125 N/A 2002 16
Choi 58/M Burkitt lymphoma IVA Small
bowel
Yes CHOP 177 Yes 2004 17
Kim 59/M Diffuse large B cell
lymphoma
IVA Systemic Yes CDE 41 Yes 2005 18
N/A, not available
COPP: cyclophosphamide, vincristine, procarbazine, prednisone
CDE: cyclophosphamide, doxorubicin, etoposide.
HAART: highly active anti-retroviral therapy
Figure 1. Overall survival of the patients.





















regression modeling that only two independent predictors are
valid, i.e. International Prognostic Index (IPI) risk group and
CD4 cell count (21). Another study of ARL patients
suggested prognostic value of HIV score based on perform-
ance status, history of prior AIDS, CD4þ cell counts (below
100/mm3, or above), IPI score and HAART with no rel-
evance of CHOP-based chemotherapy dose intensity to the
treatment outcome (22). Our series suggested that HAART
response might be predictive of survival.
The treatment of HIV-related lymphomas is evolving in
the era of HAART. Standard dose chemotherapy was
thought inadequate for immune compromised ARL patients.
However, the advent of HAART made it feasible not only to
use standard dose but also dose intensiﬁcation (4,23). The
AIDS Malignancy Consortium (AMC) 005 trial, which
compared combination chemotherapy (CHOP or reduced
CHOP) and chemotherapy plus HAART showed that
response rates and survival were improved in HAART group
while adverse events were not different between the two
groups (24). Surprisingly, CD4þ lymphocyte increased
despite the chemotherapy and HIV viral load decreased
during the HAART resulting in the decreased rate of oppor-
tunistic infections. Other approaches included infusional
regimen such as EPOCH (25). In their trial, antiretroviral
agents were stopped during chemotherapy, and resumed
immediately at the completion of chemotherapy. Complete
remission (CR) was achieved in 74% of patients with
disease-free and overall survival of 92 and 60%, respect-
ively, at a median follow-up of 53 months, the best results
ever reported. They also found that the increase of CD4þ
cell count over 100/mm3 was independent prognostic factor.
The role of rituximab in patients with HIV infection is some-
what controversial. There were two randomized trials
looking at the effect of rituximab in combination with che-
motherapy. (26,27). In patients with higher CD4þ cell
counts, the beneﬁt of rituximab may outweigh its risk,
although this has yet to be conﬁrmed in prospective, random-
ized trials speciﬁcally performed in this population (28). In
our study, none of the patients was given rituximab or infu-
sional chemotherapy, because the majority of our patients
were treated before the report of the landmark studies.
The incidence of central nervous system (CNS) involve-
ment at presentation in patients with systemic ARL has
ranged from 10 to 20% and that at relapse has ranged from 3
to 13% (29). Nowadays many experts are recommending
prophylactic IT chemotherapy for ARL patients (1,27,30).
They also emphasize supportive care measures vital in this
patient population. These include use of hematopoietic
stimulants such as G-CSF and erythropoietin for alleviation
of chemotherapy induced marrow suppression as well as tri-
methoprim–sulfamethoxazole for P. jirovecii prophylaxis. In
our series, many of the patients did not receive IT prophyla-
six, but P. jirovecii prophylaxis.
In conclusion, we report here the clinical features of ARL
patients in South Korea which are different from those
reported in western countries in distribution of pathologic
subtype, although small population of the study limited stat-
istical analysis. Given the increasing number of lymphoma
as the presentation of the AIDS deﬁning illness, a high index
of suspicion for ARL is required by clinicians caring for
patients with HIV infection as well as lymphoma, paying
attention to their non-speciﬁc presentation. A nationwide
survey of ARL must be conducted to gain further insight
into the current status in Korean ARL patients.
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